The "Penicillin Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The Penicillin Drug market studied is expected to grow with an estimated CAGR of 5.2%, over the forecast period.
Companies Mentioned
- Qiagen N.V
- Illumina, Inc.
- Becton, Dickinson and Company
- Myriad Genetics
- Thermo Fisher Scientific, Inc.
- BIOCEPT, INC.
- ANGLE plc
- Hologic, Inc.
- Lucence Diagnostics Pte. Ltd.
- Danaher Corporation
Key Market Trends
The Extended Spectrum Penicillin Segment Is Expected To Grow Faster And Dominate The Market Over The Forecast Period
Extended Spectrum Penicillins is anticipated to hold the major share of revenue in the Spectrum of Activity segment over the forecast period. The extended-spectrum penicillins consist of drugs such as carbenicilllin, mezlocillin, piperacillin, and ticarcillin. These are groups of semi-synthetic penicillin antibiotics that, because of their chemical structure, have a wider spectrum of activity than natural penicillins. They are more active against Gram-negative bacteria because they are more resistant to inactivation by extended-spectrum ?-lactamases (ESBLs) produced by these Gram-negative bacteria. Infections caused by resistant gram-negative bacteria are becoming increasingly prevalent. They are difficult to treat and are associated with high rates of morbidity and mortality.
Monotherapy with penicillin drugs is commonly used in patients with mild to moderate pneumonia. The increasing incidence of infectious diseases is predicted to accelerate the market for these penicillin drugs. As per an article by H. Regunath (2020) titled "Community-Acquired Pneumonia", the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years. Additionally, despite several developments in fighting childhood illnesses, infectious diseases remain a leading cause of death for children under the age of 5, particularly in sub-Saharan Africa and Southern Asia. According to the UNICEF report of 2019 on "Levels and Trends in Child Mortality", it was observed that for children below age 5, Pneumonia (15 percent), diarrhea (8 percent), and malaria (5 percent) remain among the leading causes of death globally. This shows that infectious diseases remain a leading cause of death among children under age 5 with most deaths due to Pneumonia.
Additionally, few players are trying to address the need for a new class of antibiotics required to treat emerging resistance bacteria. For instance, Qpex Biopharma is developing an ultra-broad-spectrum oral beta-lactamase inhibitor (QPX7728) for use in combination with beta-lactam antibiotics for drug-resistant gram-negative bacterial infections. ? On the basis of the above-mentioned factors, it is expected that the penicillin drug segment will augment over the forecast period.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America holds the major market share in the Penicillin Drug market and is expected to dominate the overall market throughout the forecast period. Penicillin is a widely used antibiotic prescribed to treat infectious diseases caused by bacteria such as staphylococci and streptococci. As per the Centers for Disease Control and Prevention, as many as 120,000 people suffered from bloodstream Staphylococcus aureus infections in the United States in 2017, and nearly 20,000 died, according to the report by CDC. Another highly infectious disease pneumonia caused by viruses, bacteria, or fungi is also on the rise in the region.
The major driver for this trend is the increasing burden of infectious diseases?, which leads to an increase in the use of various antibiotics. Age also has a significant impact on the risk of contracting any infectious disease, with both pediatric and geriatric populations with higher rates of getting infected.
According to an article by Forest W. Arnold (2020) titled "Older Adults Hospitalized for Pneumonia in the United States: Incidence, Epidemiology, and Outcomes", where the author estimated the burden of community-acquired pneumonia (CAP) in the older adult population of the United States found that the incidence of CAP was about 2100 per 100,000 population. The number corresponds to 970,000 older adults in the United States hospitalized per year with CAP. The study reported 30-day mortalities of 14% for ward patients and 33% for ICU patients, thus showing significant differences and high mortality. According to American thoracic Society (2019), there are 120 million episodes of pneumonia per year in children under 5, over 10% of which progress to severe episodes.
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Infectious Diseases?
4.2.2 Increasing R and D Activities in the Pharmaceutical Industry
4.2.3 Increasing Demand and Development of Generic Drugs
4.3 Market Restraints
4.3.1 Increasing Resistance to Anti-microbials
4.3.2 Discovery and Fierce Competition With New Class of Diverse Antibacterials
4.3.3 Stringent Regulatory Framework
4.4 Porter's Five Force Analysis
5 MARKET SEGMENTATION
5.1 By Source
5.2 By Class
5.3 By Route of Administration
5.4 By Spectrum of activity
5.5 By Distribution Channel
5.6 Geography
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/jgso2b
View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005923/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
